Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Transgenic Group's 5-Year ROIIC % for the quarter that ended in Mar. 2026 was -31.35%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Transgenic Group's 5-Year ROIIC % or its related term are showing as below:
TSE:2342's 5-Year ROIIC % is ranked worse than 58.16% of 1171
companies
in the Biotechnology industry
Industry Median: -11.13
vs TSE:2342: -31.35
Transgenic Group (TSE:2342) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Transgenic Group 5-Year ROIIC % Related Terms
Transgenic Group 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Transgenic Group's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2342 vs VRTX, REGN, RVMD: 5-Year ROIIC % Comparison
For the Biotechnology subindustry, Transgenic Group's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transgenic Group 5-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transgenic Group's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Transgenic Group's 5-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Transgenic Group (TSE:2342) has a 5-Year ROIIC % of -31.35 as of Mar. 2026. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Transgenic Group and its competitors. According to the industry distribution chart, Transgenic Group ranks #681 out of 1171 companies in the Biotechnology industry, placing it in the top 58.2%.
Is Transgenic Group's 5-Year ROIIC % too high?
Transgenic Group's current 5-Year ROIIC % is -31.35. Based on the distribution chart, Transgenic Group ranks #681 out of 1171 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Transgenic Group has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Transgenic Group's 5-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgenic Group ranks #681 out of 1171 companies for 5-Year ROIIC %. This places Transgenic Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Biotechnology company?
A good 5-Year ROIIC % depends on the Biotechnology industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Transgenic Group and its competitors. Transgenic Group's current 5-Year ROIIC % is -31.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgenic Group stock overvalued right now?
Based on GuruFocus' analysis, Transgenic Group (TSE:2342) is currently considered Modestly Undervalued. The stock's GF Value™ is 円255.54, compared to a current price of 円221.00 — trading 13.5% below its estimated fair value. The current 5-Year ROIIC % is -31.35. Transgenic Group's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Transgenic Group (TSE:2342), the current 5-Year ROIIC % is -31.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transgenic Group (TSE:2342) Overvalued in 2026?
Based on GuruFocus' analysis, Transgenic Group stock appears to be undervalued.
The current stock price of 円221.00 is trading 13.5% below its estimated GF Value™ of 円255.54.
GuruFocus considers Transgenic Group to be Modestly Undervalued.
Key valuation signals for TSE:2342:
5-Year ROIIC %: -31.35
GF Value™: 円255.54 vs. price of 円221.00 (13.5% below fair value)
No single metric tells the full story. See the TSE:2342 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.
61GF Score
Get the complete analysis for TSE:2342
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2342 has been successfully added to your 
